All In Biotech

Drug Trial Radar · NCT04178577

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

A Phase 1, Open-Label Study to Assess the Pharmacokinetics and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees of Renal Function

Last checked: Nov 19, 2026Latest source record: Nov 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Dec 6, 2019

Primary completion

Sep 6, 2020

Study completion Sep 11, 2020

Sponsor

Lead sponsor
Spero TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Evaluation of the pharmacokinetics (PK) of TBPM-PI-HBr in subjects with normal renal function, subjects with various degrees of renal insufficiency, and subjects with end-stage renal disease (ESRD) receiving hemodialysis (HD) therapy.

Conditions

  • Renal Impairment

Interventions

  • Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)Drug

    Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Apparent total body clearance (CL/F).Time frame: 72 hours post dose
  2. Area under the curve from time zero to the last quantifiable sample (AUC0-last).Time frame: 72 hours post dose
  3. Area under the curve extrapolated to infinity (AUC0-∞).Time frame: 72 hours post dose
  4. Apparent steadystate volume of distribution (Vss/F).Time frame: 72 hours post dose
  5. Maximum plasma concentration (Cmax).Time frame: 72 hours post dose
  6. Time to the maximum plasma concentration (Tmax).Time frame: 72 hours post dose
  7. Terminal elimination half-life (t1/2).Time frame: 72 hours post dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Medical Facility

    Miami, Florida

  • Medical Facility

    Orlando, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.